These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. A new triple combination cystic fibrosis transmembrane regulator modulator. Perrem L; Ratjen F Lancet Respir Med; 2023 Jun; 11(6):499-500. PubMed ID: 36842448 [No Abstract] [Full Text] [Related]
64. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
65. Cystic Fibrosis: Emerging Understanding and Therapies. Rey MM; Bonk MP; Hadjiliadis D Annu Rev Med; 2019 Jan; 70():197-210. PubMed ID: 30312551 [TBL] [Abstract][Full Text] [Related]
66. Cystic fibrosis: bridging the treatment gap in early childhood. Davies JC Lancet Respir Med; 2013 Aug; 1(6):433-4. PubMed ID: 24429232 [No Abstract] [Full Text] [Related]
67. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Kaiser J Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790 [No Abstract] [Full Text] [Related]
68. Highlights of the North American Cystic Fibrosis Conference 2011. Pabary R; Thursfield R; Davies JC J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S9-13. PubMed ID: 22688370 [No Abstract] [Full Text] [Related]
69. Ivacaftor in a G551D homozygote with cystic fibrosis. Harrison MJ; Murphy DM; Plant BJ N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763 [No Abstract] [Full Text] [Related]
70. A new chapter in therapy for cystic fibrosis. Bilton D Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158 [No Abstract] [Full Text] [Related]
71. CFTR protein repair therapy in cystic fibrosis. Quintana-Gallego E; Delgado-Pecellín I; Calero Acuña C Arch Bronconeumol; 2014 Apr; 50(4):146-50. PubMed ID: 24095197 [TBL] [Abstract][Full Text] [Related]
72. A cocktail drug therapy for patients with cystic fibrosis? Chen JH J Cyst Fibros; 2014 Sep; 13(5):489-90. PubMed ID: 25088968 [No Abstract] [Full Text] [Related]
73. Another Beginning for Cystic Fibrosis Therapy. Davis PB N Engl J Med; 2015 Jul; 373(3):274-6. PubMed ID: 25981385 [No Abstract] [Full Text] [Related]
74. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599 [TBL] [Abstract][Full Text] [Related]
77. Cystic fibrosis in an era of genomically guided therapy. Barrett PM; Alagely A; Topol EJ Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736 [TBL] [Abstract][Full Text] [Related]
78. Game Changers. Ulster Med J; 2015 Oct; 84(3):218-9. PubMed ID: 26668427 [No Abstract] [Full Text] [Related]
79. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054 [TBL] [Abstract][Full Text] [Related]
80. Therapy for cystic fibrosis--the end of the beginning? Davis PB N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]